



DAC A
BOX 209 A

PTO/SB/21 (02-04)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	09/842,993 09/442,863
Filing Date	April 27, 2001
First Named Inventor	Benjamin Rovinski
Art Unit	
Examiner Name	
Total Number of Pages in This Submission	11
Attorney Docket Number	1038-1142 MIS:ah

RECEIVED

JUL 12 2004

OFFICE OF PETITIONS

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance communication to Technology Center (TC)
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input checked="" type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	<input type="checkbox"/> Postcard
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	<input type="checkbox"/> Sequence Listing in computer readable form and hard copy
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Michael I. Stewart (Reg. No. 24,973)
Signature	
Date	July 6, 2004

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below

Typed or printed name	Michael I. Stewart
Signature	
Date	July 6, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



#15

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Benjamin Rovinski, et al.
Appl'n. No. : 09/842,883
Filed : April 27, 2001
Title : IMMUNIZING AGAINST HIV INFECTION
Docket No. : 1038-1142 MIS/ah
Date : July 6, 2004

RECEIVED

BY COURIER

JUL 12 2004

Mail Stop Petitions
Commissioner of Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
U.S.A.

OFFICE OF PETITIONS

**RENEWED PETITION TO REVIVE ABANDONED APPLICATION
UNDER 37 CFR 1.137(a)**

Sir:

This Renewed Petition is submitted in response to the Decision on Petition dated May 7, 2004.

The Examiner indicates that the Petition lacked the required reply to the "Notice to Comply with Requirements for Patent Application Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures" dated July 10, 2002.

As explained in the Petition submitted March 2, 2004, the Applicants had already complied with this requirement by our letter of November 12, 2001 received in the PTO on November 3, 2001.

However, having regard to the Decision, submitted herewith are:

1. Sequence Listing in computer readable form and hard copy form.

2. Amendment directing entry of the Sequence Listing into the specification

3. It is hereby stated, under the signature of the undersigned, that the content of the paper and computer-readable forms of the Sequence Listing are the same and involve no new matter.

It is submitted that, under the circumstances, this application should be revived.

Respectfully submitted,



Michael I. Stewart

Reg. No. 24,973

Toronto, Ontario, Canada,
(416) 595-1155
FAX No. (416) 595-1163



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Benjamin Rovinski, et al.
Appl'n. No. : 09/842,883
Filed : April 27, 2001
Title : IMMUNIZING AGAINST HIV INFECTION
Grp./A.U. :
Examiner :
Docket No. : 1038-1142 MIS:ah
Date : July 2, 2004

BY COURIER

Mail Stop Sequence
Commissioner of Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
U.S.A.

RECEIVED

JUL 12 2004

OFFICE OF PETITIONS

VOLUNTARY AMENDMENT

Dear Sir:

Please amend this application in the following manner:

In the Disclosure:

Please insert the attached Sequence Listing immediately following page 20 and before the claims.

REMARKS

The Sequence Listing is added to the specification hereby.

Respectfully submitted

Michael I. Stewart
Reg. No. 24,973

Toronto, Ontario, Canada
(416) 595-1155
FAX No. (416) 595-1163



21/6

SEQUENCE LISTING

<110> Rovinski, Benjamin
Tartaglia, James
Cao, Shi-Xian
Persson, Roy
Klein, Michel H.

<120> IMMUNIZING AGAINST HIV INFECTION

<130> 1038-1142 MIS

<140> 09/842,883

<141> 2001-04-27

<150> 60/200,011

<151> 2000-04-27

<160> 19

<170> PatentIn Ver. 2.1

<210> 1

<211> 1345

<212> DNA

<213> Human immunodeficiency virus

<400> 1

ttttttcat tatttagaaa ttatgcattt tagatctta taagcggccg tgattaacta 60
gtcataaaaa cccgggatcg attctagact cgagggtacc ggatcttaat taattagtca 120
tcagggcagg cgagaacgag actatctgct cgttaattaa ttaggtcgac ggatccccca 180
acaaaaacta atcagctatc ggggttaatt aattagttat tagacaagggt gaaaacgaaa 240
ctattttagt cttaattaaat tagagcttct ttattctata cttaaaaagt gaaaataaaat 300
acaaaggttc ttgagggttg tggtaattt aaagcgagaa ataattcataa attatttcat 360
tatcgcata tccgttaagt ttgtatcgta atgccactaa cagaagaagc agagctagaa 420
ctggcagaaa acagagagat tctaaaagaa ccagtacatg gagtgttata tgaccatca 480
aaagacttaa tagcagaaaat acagaagcag gggcaaggcc aatggacata tcaaatttat 540
caagagccat taaaaatct gaaaacagga atggagtggta gatttggattc tagattagca 600
tttcatcactg tagctagaga attacatcct gaatattta aaaattgtat ggcaatattc 660
caaagtagca tgacaaaaat ctttagagcct ttttagaaaac aaaatccaga catagttatc 720
tatcaataca tggatgattt gtatgttaga tctgacttag aaatagggca gcataagaaca 780
aaaatagagg agctgagaca acatctgtt aggtggggac ttacaaccat ggtaggttt 840
ccagtaacac ctcaagttacc tttaaagacca atgacttaca aagcagctgt agatcttct 900
cacttttaa aagaaaaagg aggttttagaa gggctaattc attctcaacg aagacaagat 960
attcttgatt tgtggattt tcatacacaa ggatatttc ctgattggca gaattacaca 1020
ccaggaccag gagtcagata cccattaacc tttgggttgt gctacaagct agtaccaatg 1080
attgagactg taccagtaaa attaaagcca ggaatggatg gccaaaagt taaaacatgg 1140
ccattgacag aagaaaaaat aaaagcatta gttagaaattt gtacagagat ggaaaaggaa 1200
ggggaaattt caaaaattgg gccttaattt ttctgcagcc cgggggatcc tttttatagc 1260
taattagtca cgtaccttgc agagtaccac ttcagctacc tctttgtgt ctcagagtaa 1320
ctttcttaa tcaattccaa aacag 1345

<210> 2

<211> 64

<212> DNA

<213> Human immunodeficiency virus

<400> 2
atcatcatcg gatccgggg tcgcgatatc cgttaagttt gtatcgtaat gaaagtgaag 60
gacc 64

<210> 3
<211> 38
<212> DNA
<213> Human immunodeficiency virus

<400> 3
atcatcatcg gatccgggg ttatagcaaa gcccttc 38

<210> 4
<211> 28
<212> DNA
<213> Human immunodeficiency virus

<400> 4
gcactttct atagtcttga tatagtac 28

<210> 5
<211> 33
<212> DNA
<213> Human immunodeficiency virus

<400> 5
agccggggcg cagaaatgta tggaaattgg cac 33

<210> 6
<211> 34
<212> DNA
<213> Human immunodeficiency virus

<400> 6
atacatttct gcgccccggc tggtttgcg attc 34

<210> 7
<211> 26
<212> DNA
<213> Human immunodeficiency virus

<400> 7
gaagaattcc cctccacaat taaaac 26

<210> 8
<211> 37
<212> DNA
<213> Human immunodeficiency virus

<400> 8

tgtggagggg aattcttcta ctgtaataca acacaac

37

<210> 9
<211> 38
<212> DNA
<213> Human immunodeficiency virus

<400> 9
atcatcatcg gatccgggg ttatagcaaa gcccttc

38

<210> 10
<211> 24
<212> DNA
<213> Human immunodeficiency virus

<400> 10
tagtggaaa gagatttca gacc

24

<210> 11
<211> 37
<212> DNA
<213> Human immunodeficiency virus

<400> 11
tttaagctt ttatccctgc ctaactctat tcactat

37

<210> 12
<211> 24
<212> DNA
<213> Human immunodeficiency virus

<400> 12
tagtggaaa gagatttca gacc

24

<210> 13
<211> 47
<212> DNA
<213> Human immunodeficiency virus

<400> 13
cctcctacta tcattatgaa tatttttt tctcttgca ccactct

47

<210> 14
<211> 48
<212> DNA
<213> Human immunodeficiency virus

<400> 14
agagtggc agagagaaaa aagaatattc ataatgatag taggaggc

48

<210> 15
<211> 37
<212> DNA
<213> Human immunodeficiency virus

<400> 15
tttaagctt ttatccctgc ctaactctat tcactat

37

<210> 16
<211> 4434
<212> DNA
<213> Human immunodeficiency virus

<400> 16
gagctcgccg ccgcctatca aaagtcttaa tgagtaggt gtagatagta tagatattac 60
tacaaaaggta ttcataatttc ctatcaattc taaagtagat gatattaata actcaaagat 120
gatgatagta gataatagat acgctcatat aatgactgca aatttgacg gttcacattt 180
taatcatcac gcgttcataa gttcaactg catagatcaa aatctcacta aaaagatagc 240
cgatgtattt gagagagatt ggacatctaa ctacgctaaa gaaattacag ttataaataa 300
tacataatgg attttgttat catcagttat attaacata agtacaataa aaagtattaa 360
ataaaaatac ttacttacga aaaaatgact aattagctat aaaaacccag atctctcgag 420
gtcgacggta tcgataagct tgatatcgaa ttctataaaaa ttattgtgt ctacacatcc 480
tttgttaatt gacatctata tattctttt tataatcaac tctaattact ttaactttt 540
cagtttccc taccagttt tccctatatt caacatatct atccatatgc atcttaacac 600
tctctgccaa gatagcttca gagtggat agtcaaaaag ataaatgtat agagcataat 660
ccttctcgta tactctgccc ttattacat cgccgcatt gggcaacgaa taacaaaatg 720
caagcatacg atacaactt aacggatatac gcgataatga aataatttatt gattattct 780
cgcttcaat ttaacacaac cctcaagaac ctttgtattt attttactt tttaagtata 840
gaataaaagaa agctctaatt aattaatgaa cagattgttt cgccccccc ttggcgtatc 900
actaattaat taacccgggc tgagctcga ggaattcaac tataatcgaca tatttcattt 960
gtatacacat aaccattact aacgtagaaat gtataggaag agatgtaacg ggaacagggt 1020
tttgttattt gcaaactatt ctaatacata attcttctgt taatacgtct tgcacgtaat 1080
ctattataga tgccaagata tctatataat tattttgtaa gatgatgtt actatgtat 1140
ctatataagt agtgaataaa ttcatgtatt tcgatataatg ttccaactct gtcttgcgt 1200
tgtcttagttt cgtaatatct atagcatcct caaaaaatattt attccatctt attcccaagt 1260
cttcagttct atcttctaaa aaatcttcaa cgtatggat ataataatctt attttacctc 1320
ttctgatatc attaatgata tagttttga cactatctt tgtcaattga ttcttattca 1380
ctatatactaa gaaacgata gcgtccctag gacgaaatc tgccattat atctctatta 1440
tagcttctgg acataattca tctattatac cagaattat gggaaactatt ccgtatctat 1500
ctaacatagt tttaaaaag tcagaatcta agacctgatg ttcatatatt gtttcataca 1560
tgaatgatc tctattgtatc atagtgacta ttcatgtt taaaattgg taactcattc 1620
tataatgtct ttctttgtt atgaaggata gaatatactc aatagaattt gtaccaacaa 1680
actgttctct tatgaatcgt atatcatcat ctgaaataat catgtaaaggc atacatttaa 1740
caattagaga ctgtctcct gtatcaata tactattctt gtgataattt atgtgtgagg 1800
caaatttgcac cacttctttt aattttgtt tagtagatataa caaatccat ggagctacag 1860
ttcttggctt aaacagatataat agttttctg gaacaaattc tacaacatta ttataaagga 1920
cttgggtatc ataagtggaa tggaaatccta tttaattaa tgctatcgca ttgtcctcgat 1980
gcaaatatcc aaacgctttt gtatgtat ggcatttgcatt gtctagaaac gctctacgaa 2040
tatctgtgac agatatactc tttagagaat atactatcg cgttaatagt actacaattt 2100
gtattttta atctatctca ataaaaaaat taatatgtat gattcaatgt ataactaaac 2160
tactaactgt tattgataac tagaattcaga atctaattgtat gacgtaaaccg agaagttat 2220
ctactgccaat tttagctgca ttatctttag catctcgatc agatttcca tctgcctt 2280
cgataactct tccgtcgatc tctacacagg cataaaatgtt aggagatgtt ctggcccaa 2340
ctgattcaat acgaaaagac caatctctt tagttatttgc gacgtactca ttaataatgg 2400
tgacaggggtt agcatcttca caatcaataa tttttttagc cggataataaca tcatcaaaaag 2460
acttataatgc tctctcattt gatttttcgc gggataacatc atctattatg acgtcagcc 2520

tagcatcagc atccggctta tccgcctccg ttgtcataaa ccaacgagga ggaatatcg 2580
cggagctgta caccatagca ctacgttcaa gatcgtagag agctttatta acttcgc 2640
tctccatatt aagttgtcta gttagttgtg cagcagtagc tccttcgatt ccaatgttt 2700
taatagccgc acacacaatc tctgcgtc aacgctcgat aatatacgat tttagacattt 2760
tttagagagaa ctaacacaac cagcaataaa actgaaccta ctttatcatt ttttattca 2820
tcatcctctg gtgggtcgat gttctatcg aatgtatcg tgattaaccc gtcatctata 2880
ggtgatgctg gttctggaga ttctggagga gatggattat tatctggaa aatctctgtt 2940
atttccttgt tttcatgtat cgattgcgtt gtaacattaa gattgcgaaa tgctctaat 3000
ttgggaggct taaagtgttgc ttgcataatct ctacacgcgt gtctactatg tggagggtcg 3060
tcagctgctc tagttgaat catcatcgcc gtagtattcc tactttaca gttaggacac 3120
ggtgtattgt atttctcgatc gagaacgtt aaataatcgat tgtaactcac atcctttatt 3180
ttatctatat tttatcttac tccttcattt atgcattttt taccgaataa gagatagcga 3240
agaattctt tttattgtt aactagtcaa atgagttatataaattgaaa aagtaaaataa 3300
taaatcatat aataatgaaa cgaatataatca gtaatagaca ggaactggca gattcttctt 3360
ctaataatcgat aagtactgct aaatctccaa aatttagataa aaatgataca gcaaatacag 3420
cttcattcaa cgaatttaccc tttaattttt tcagacacac cttattacaa actaactaag 3480
tcagatgatg agaaagtaaa tataaatttta acttatgggt ataataat aaagattcat 3540
gatattaata atttacttaa cgatgttaat agacttattt catcaacccc ttcaaacctt 3600
tctggatatt ataaaatacc agttatgtt attaaaatag attgtttaag agatgttaat 3660
aattatttgg aggttaagga tataaaatattt gtcatacttt cacatggaaa tgaatttac 3720
aatattaata attatgtatg gaattttta ggattttacag ctgttatatg tatcaacaat 3780
acaggcagat ctatggttat ggtaaaacac tgtaacggga agcagcattc tatggtaact 3840
ggctatgtt taatagccag atcattttac tctataaaaca ttttaccaca aataatagga 3900
tcctctagat atttaatattt atatctaaca acaacaaaaa aatttaacga tttatggca 3960
gaagtattttt ctactaataa agataaagat agtctatctt atctacaaga tatgaaagaa 4020
gataatcatt tagtagtagc tactaatatg gaaagaaaatg tataaaaaaa cgtggaaagct 4080
tttatattaa atagcatattt actagaagat tttttatctt gacttagtat aacaaaaacag 4140
ttaaatgccat atatcgattt tatatttcat cataacagta gtacattat cagtgtatata 4200
ctgaaacgat ctacagactc aactatgcaaa ggaataagca atatgccaat tatgtctaat 4260
attttactt tagaactaaa acgttctacc aataactaaa ataggatacg tgataggctg 4320
ttaaaaagctg caataaaatag taaggatgtt gaaagaaatac tttgttctat accttcggag 4380
gaaagaacct tagaacaact taagtttaat cttttttttttaatgaaagg tacc 4434

<210> 17
<211> 4434
<212> DNA
<213> Human immunodeficiency virus

<400> 17
ctcgagcgcc ggcggatagt tttcagaattt actcaatcca catctatcat atctataatg 60
atgtttccat aagtataaaag gatagttaaattttcatctatataattt tgatgtttcta 120
ctactatcat ctattatctt tgcgagttttaactgtatgtt ttaaacctgc caagtgtaaa 180
atttagtagtg cgcaagtttcaaaatgtac gtatctatgtt ttagagtgtat ttttctatcg 240
gctacataaa ctctctctaa cctgttagattt gatgcgatattt cttaatgtc aatattttattt 300
atgtattacc taaaacacataa gtatgtcaataa taaattgtat tcatgtttattt tttcataattt 360
tatattttatg aatgaatgtt tttttactgtt ttaatcgata tttttgggtc tagagagctc 420
cagctgccccat agcttattcga actatagctt aagtattttt aataactaca gatgtgttagg 480
aaaacattaa ctgttagatataaggaaaac atatttagttt agatttagtga aattgaaaat 540
gtcaaaagggtt atggtcaaat aggatataa gttgtataga taggtatacg tagaattgtg 600
agagacgggtt ctatcgaaatg ctcaacttca tcaatgttttcatatcatat tctcgatata 660
ggaagagcat atgagacgggg aaataatgtt gggggcgtaa cccgggttgcatttatttac 720
gttcgtatgc tatgtttgaa ttgcctatag cgcttattactt ttatataataa ctaataaaaga 780
gcaaaaggtaa aattgtgttg ggagttcttg gaaacataaa taaaaggtaa aaatttcatat 840
tttatttctt tcgagatattt ttaattactt gtctaaacaaa gcaaaaggggg aaccgcata 900
tgatataattt attggggcccg acgtcgagct ccttaagttg atatagctgt ataaaggtaa 960
catatgttgc ttggtaatgtt ttcgtatctt catatccttc tctacattgc ctttgc 1020

aacaactaag cgtttgataa gattatgtat taagaagaca attatgcaga acgtgcatta 1080
gataatatct acggttctat agatataattt ataaaacatt ctactacaat tgatacacta 1140
gatataattca tcacattatt aagtacataa agctatatac aagggttggaa cagaaacact 1200
acagatcaaa gcattataga tattcgtagga gtttttata taagcgata taagggttca 1260
gaagtcaaga tagaagattt tttagaagtt gcataccctt tattattaga taaaatggag 1320
aagactatag taattactat atcaaaaact gtgatagaag acagttact aagaataagt 1380
gatatagatt ctttgcctat cgagggttc ctgcttgatg acggtaatta tagagataat 1440
atcgaagacc tttttaatg agataatatg gtcttaatta cccttgataa ggcatacgata 1500
gattgtatca aaattcttc agtcttagat tctggactac aagtatataa ccaagtatgt 1560
actttactag agataactac tatcactgtat aaagtaagag acttttaacc attgagtaag 1620
atatatacga aaggaacaac tacttcctat ctttatatgat ttatcttaaa catgggtt 1680
tgacaagaga atacttagca tatagtagta gacttttata gtacattccg tatgtaaatt 1740
gttaatctct gaacagagga caatagttt atgataagaa cactattaaa tacacactcc 1800
gtttaaacag gtgcaagaaa taaaacaat atcatctata gtttaggtt cctcgatgtc 1860
aagaaccgaa ttgtctata tcaaaaagac cttgtttaag atgttgaat aatatttcct 1920
gaaaccatc tattcacccct actttaggtt aaaattaatt acgatagcgt aacaggagca 1980
cgtttatagg ttgcgaaaaa cactatcata ccgttaagtaa cagatcttt cgagatgtt 2040
atagacactg tctatagtag aaatctctt tatgatcgc gcaattatca tgatgttaaa 2100
cataaaaaat tagatagat tatttttta attatacata ctaagttaca tattgattt 2160
atgattgaca ataactattt atcttagtct tagattacta ctgcatttgt tcttcaaata 2220
gatgacgggtt aaatcgacgt aataaaaatc gttagagcaaa tctaaaagggt agacggaata 2280
gcttatgaga aggcaactac agatgtgtcc gtatttaca tcctctcaat gatccgggtt 2340
gactaagttt tgctttctg gtttagagaga atcaataaaac cgtcatgagt aattattacc 2400
actgtcccaa tcgtagaaaag gtttagttt aaaaaaatcg gccttattgtt agtagtttc 2460
tgaatactag gagagagtaa ctaaaaagcg ccctatgttag tagataatac tgcagtcggt 2520
atcgtagtcg tggccaat aggccggaggc aacagtattt gggtgctcct ctttatagca 2580
gcctcgacat gtggtatcgt gatgcaactt ctgcattgtc tcgaaaataat tgaagagcga 2640
agaggtataa ttcaacagat caatcaacac gtcgtcatcg aggaagctaa gtttacaaaa 2700
attatcgccg tttgtgttag agacgcgtc ttgcgagcag ttatatctag aatctgtaaa 2760
aatctctctt gttgtgttg gtcgttattt tgacttggat gaaatagtaa aaaaataagt 2820
agtaggagac caccacccat caaagatagc ttacatcgag actaatttggg cagtagat 2880
ccactacgac caagacccct aagacccctt ctacctaata atagaccttc ttagagacaa 2940
taaaggaaca aaagtacata gctaacgcaaa cattgttattt ctaacgcctt acgagattt 3000
aaccctccga atttcacaac aaacgtttaga gatgtgcgcg cagattgatc acctccaagc 3060
agtcgacgag atcaaaactt gtagtagccg catcataagg atgaaaatgt caatccgtt 3120
ccacataaca taaagagcag ctcttgcaat tttattagca acattgagtg taggaaataa 3180
aatagatata acataagatg aggaaagaat tacgtttttt atggcttattt ctctatcgct 3240
tccttaagaa aaataactaa ttgtatcgat tttttttt tattatata tttctt 3300
atttagtata ttattacttt gttttatgtt cattatctgt ctttgaccgt ctaagaagaa 3360
gattacttca ttcatgacga tttagaggtt ttaatctatt tttactatgt cgtttatgtc 3420
gaagtaagtt gcttaatgga aaattttttt agtctgtgtg gaataatgtt tgattgattc 3480
agtcgtactac tctttcattt atattttat tgaataccctt tattatata tttctt 3540
ctataattt taaatgttattt gctacaattt tctgaataag gtatgtgggg aagtttggaa 3600
agacctataa tttttatgg tcaattacta taattttattt taacaaattt tctacattt 3660
ttaataaaacc tccatttcctt atattttat cagatagaaa gtgtacccctt acttaatgg 3720
ttataattt taataactatc cttttttttt cctaaatgtc gacaatatac atagttgtt 3780
tgtccgtcta gataccaata ccattttgtg acattgcct tcgtcgtaag ataccattga 3840
ccggatcacaa attatcggtc tagttttttt agatattttt aaaaatgtt ttattatcc 3900
aggagatcta taaattataa tatagattgt ttgtttttt ttaatttgcgat acataccgt 3960
cttcataaaaa gatgattttt tctttttt tcaatcgat tttttttt atactttctt 4020
ctatttagtaa atcatcatcg atgatttttac ctttcttac atatgtttt gcaccccttgc 4080
aaatataattt tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt 4140
aatttacggt tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt 4200
gactttgtca gatgtctgtt ttgtatcgat cttttttt tttttttt tttttttt tttttttt 4260
taaaatttgcgat tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt 4320
aatttgcac gttttttt tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt 4380
ctttcttgaa atcttgcgtt tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt 4434

<210> 18
<211> 88
<212> PRT
<213> Human immunodeficiency virus

<400> 18
Gln His Arg Cys Met Arg Lys Tyr Asn Val Asp Ile Tyr Gly Lys Thr
1 5 10 15

Tyr Asp Val Arg Ile Val Lys Val Lys Val Thr Lys Gly Val Leu Lys
20 25 30

Asp Arg Tyr Glu Val Tyr Arg Asp Met His Met Lys Val Ser Glu Ala
35 40 45

Leu Ile Ala Glu Ser His Pro Tyr Asp Phe Leu Tyr Ile Tyr Leu Ala
50 55 60

Tyr Asp Lys Glu Tyr Val Arg Gly Lys Ile Val Asp Gly Ala Asn Pro
65 70 75 80

Leu Ser Tyr Cys Phe Ala Leu Met
85

<210> 19
<211> 190
<212> PRT
<213> Human immunodeficiency virus

<400> 19
Phe Arg Ile Ile Val Tyr Gly Leu Leu Lys Asp Val Ala Leu Lys Ala
1 5 10 15

Ala Asn Asn Lys Ala Asp Arg Lys Ser Lys Gly Asp Ala Lys Asp Phe
20 25 30

Val Arg Gly Asp Ile Asp Val Cys Ala Tyr Phe Thr Pro Ser Asn Ser
35 40 45

Pro Gly Val Ser Glu Ile Arg Phe Ser Trp Asp Arg Lys Thr Ile Gln
50 55 60

Cys Tyr Glu Asn Ile Ile Thr Val Pro Asn Ala Asp Lys Trp Asp Ile
65 70 75 80

Ile Lys Lys Ala Pro Ile Val Asp Asp Phe Ser Lys His Asp Glu Arg
85 90 95

Met Ser Lys Glu Arg Ser Val Asp Asp Ile Ile Val Asp Ala Met Ala
100 105 110

Asp Ala Asp Pro Lys Asp Ala Glu Thr Thr Met Phe Trp Arg Pro Pro
115 120 125

Ile Asp Asp Ser Ser Tyr Val Met Ala Ser Arg Gln Leu Asp Tyr Leu
130 135 140

Ala Lys Asn Val Glu Arg Lys Glu Met Asn Leu Gln Arg Thr Leu Gln
145 150 155 160

Ala Ala Thr Ala Gly Glu Ile Gly Ile Asn Lys Ile Ala Ala Cys Val
165 170 175

Ile Glu Ala Asp Ser Arg Glu Asp Ile Tyr Ile Lys Ser Met
180 185 190